What is the recommended management of immune reconstitution inflammatory syndrome (IRIS) in HIV‑positive patients on antiretroviral therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Immune Reconstitution Inflammatory Syndrome (IRIS)

Continue antiretroviral therapy (ART) in most cases of IRIS while treating the underlying opportunistic infection and adding corticosteroids for severe manifestations 1, 2.

Core Management Principles

The management of IRIS follows a three-pronged approach that addresses the underlying infection, controls excessive inflammation, and maintains immune reconstitution:

1. Continue ART (Primary Strategy)

In the vast majority of IRIS cases, ART should be continued without interruption 1, 2. The guideline evidence strongly supports maintaining ART because:

  • The benefits of ongoing immune reconstitution outweigh the risks of inflammatory complications
  • Interrupting ART risks disease progression and mortality in patients with advanced HIV
  • Most IRIS cases are self-limited and resolve with supportive care

ART interruption should only be considered in life-threatening IRIS 3, 2. This is reserved for extreme circumstances where the inflammatory response poses immediate mortality risk.

2. Optimize Treatment of the Underlying Opportunistic Infection

Ensure appropriate pathogen-specific therapy is optimized 2, 4. This is critical because:

  • IRIS represents an inflammatory response to existing antigens
  • Reducing antigenic burden helps control the inflammatory cascade
  • Common IRIS-associated infections include:
    • Mycobacterium tuberculosis (most common)
    • Mycobacterium avium complex
    • Cryptococcal meningitis
    • Cytomegalovirus retinitis
    • Pneumocystis pneumonia
    • Kaposi sarcoma 1

3. Anti-inflammatory and Immunomodulatory Therapy

Corticosteroids are the primary anti-inflammatory treatment for moderate-to-severe IRIS 2. The evidence hierarchy for anti-inflammatory management:

First-line: Corticosteroids

  • The only treatment with clinical trial data (specifically for paradoxical tuberculosis-associated IRIS) 2
  • Most frequently used agent across all IRIS manifestations
  • Indicated for severe cases with significant morbidity
  • Caution: In Kaposi sarcoma-associated IRIS, steroids may cause paradoxical worsening 5

Second-line: NSAIDs

  • For mild-to-moderate cases 3, 6, 2
  • Lower risk profile than corticosteroids
  • Useful when steroid side effects are concerning

Emerging Therapies (Severe, Refractory Cases)

Recent case reports describe novel approaches for life-threatening IRIS refractory to standard treatment:

  • JAK inhibitors (Janus kinase inhibition) 7
  • Cytokine adsorption therapy (CytoSorb®) 7
  • Other agents with limited evidence: pentoxifylline, montelukast, thalidomide, hydroxychloroquine 2

4. Procedural Interventions

Drainage procedures and surgery play important roles in specific IRIS presentations 2:

  • Aspiration of abscesses or fluid collections
  • Surgical debridement when indicated
  • Pericardial drainage for effusions (as in KS-IRIS with cardiac involvement) 5

Clinical Pitfalls and Caveats

Diagnostic Challenges

IRIS is a clinical diagnosis of exclusion 3, 8. Before diagnosing IRIS, you must rule out:

  • Treatment failure of the opportunistic infection
  • New opportunistic infections
  • Drug resistance
  • Medication non-adherence
  • Drug toxicity or interactions

Risk Factors to Recognize

Patients at highest risk for IRIS have 3, 6, 8:

  • CD4 count <200 cells/μL at ART initiation (especially <50 cells/μL)
  • High baseline HIV viral load
  • Rapid virologic response to ART
  • High antigenic burden from opportunistic infection
  • Early ART initiation after starting OI treatment

Two Forms of IRIS

Understanding the distinction guides management 1:

  1. Unmasking IRIS: Previously undiagnosed OI becomes clinically apparent after ART initiation

    • Requires new diagnosis and treatment of the OI
  2. Paradoxical IRIS: Clinical worsening of a known, appropriately treated OI after ART initiation

    • Verify OI treatment is adequate before attributing to IRIS

Prevention Strategies

While not the primary question, prevention is clinically relevant 6, 8, 4:

  • Screen for and treat opportunistic infections before initiating ART when possible
  • Consider timing of ART initiation in patients with active OIs (balance IRIS risk against immunosuppression risk)
  • Ensure adequate treatment of OIs before or concurrent with ART initiation

Special Populations

HIV-negative immunocompromised patients can also develop IRIS 9, 10, including:

  • Post-chemotherapy neutrophil recovery
  • Post-transplant immunosuppression reduction
  • Rapid corticosteroid withdrawal

The management principles remain similar: treat the underlying infection, control inflammation, and carefully manage immune reconstitution.

References

Research

[Management of immune reconstitution inflammatory syndrome].

Nihon rinsho. Japanese journal of clinical medicine, 2010

Research

[Immune reconstitution inflammatory syndrome associated with invasive pulmonary fungal disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.